News

Of mice and M&A: Horizon buys Sage Labs

The U.K.'s Horizon Discovery has snapped up St. Louis-based Sage Labs for $48 million in cash and stock.

Just how big is the biosimilars business going to be in 5 years?

Thomson Reuters BioWorld took a deep dive into the subject and surfaced today with a detailed report outlining a bustling new global business with roughly 700 so-called follow-ons put in the clinic by 245 companies and institutions. Looking ahead to 2020, analysts say, you can anticipate that biosimilars will account for about $25 billion out of $100 billion in sales for off-patent biologics.

Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs.

Tonix shares battered as lead fibromyalgia drug flops in PhIIb

Shares of Tonix Pharmaceuticals were hammered early Monday after the biotech put out word that its lead drug had failed a Phase IIb study for fibromyalgia.

Alimera and pSivida finally win FDA approval for thrice-rejected drug

After a series of painful rejections, partners Alimera Sciences and pSivida have finally convinced the FDA to approve the eye drug Iluvien, sending each company's shares roaring on some renewed optimism for the long-delayed treatment.

ESMO: Bristol-Myers, Roche, AstraZeneca, GSK, Merck jostle for spotlight

Over the weekend oncology investigators from all around the world gathered in Madrid at the European Society for Medical Oncology (ESMO) 2014 Congress to review the latest advances--and setbacks--in the fast-moving field of cancer drug research. As usual, the big companies dominated the discussions, as rival oncology groups touted new data as they tried to position competing therapies in the global scramble to develop new and better cancer drugs, now one of the hottest fields in R&D.

Daiichi Sankyo bags leukemia drug in $410M Ambit buyout

About 18 months after Astellas dumped its development partnership with Ambit Biosciences on a now late-stage drug for acute myeloid leukemia, Daiichi Sankyo has stepped in to snap up the San Diego-based biotech for up to $410 million. The deal helps beef up the Japanese company's oncology pipeline.

How was HIV eradicated in one patient?

A new monkey study points to how a cancer treatment that the famous "Berlin patient" underwent may have resulted in HIV being eradicated in his body.

Biosimilars outfit Coherus pitches an $86M IPO, targeting Enbrel and Humira

Coherus Medical, a biotech developing knockoffs of some of the world's top-selling treatments, is plotting an $86 million IPO to bankroll its late-stage R&D work.

GSK taps Royal Bank of Scotland chair Philip Hampton to lead its own board

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Takeda pours $25M into biotech dealmaker BioMotiv

Takeda Pharmaceutical has stepped up with a $25 million investment in Cleveland's BioMotiv, buying into the accelerator's promise to transform academic discoveries into market-bound therapeutics.

Gilead nears EU approval for the next big thing in hep C

Gilead Sciences, already a trailblazer in hepatitis C treatment, is creeping up on its next milestone: approval for a combination therapy that promises to cure the majority of patients without the need for painful injections.

Pharmacyclics, Servier call it quits on a cancer drug

Pharmacyclics and Servier are quietly walking away from a 5-year collaboration on a new cancer treatment, leaving the former company to go it alone on mid-stage oral drug with an uncertain future.

Novo dishes on its new Seattle R&D shop and seeks out new ideas in obesity

Novo Nordisk has made it official: The Danish drugmaker is making a full-fledged go at obesity R&D, looking to build a Seattle hub and hire up some investigators as it expands its research palate.

Alzheimer's biotech Probiodrug plots a Euro IPO amid a continental boomlet

German drug developer Probiodrug is looking to go public on the Amsterdam exchange, seeking funds to advance its pipeline of treatments for Alzheimer's disease as more and more European biotechs set sights on IPOs.

Valeant talks up the billion-dollar potential of its Phase III eye drug

Valeant Pharmaceuticals is famous for its aversion to pharmaceutical R&D, but the serial acquirer makes an exception when it sees blockbuster promise in a late-stage asset. And that's the case for the glaucoma treatment Vesneo, which met its goals in pivotal trials and, according to the company, has blockbuster potential.

Novartis' blockbuster hopeful scores a win in psoriatic arthritis

Jockeying with a slew of next-generation treatments, Novartis' new anti-inflammatory drug succeeded in two Phase III trials on patients with psoriatic arthritis, stoking the company's hopes of snagging significant market share once it wins approval.

Regado slashes staff to preserve cash following PhIII fiasco

Regado had all of its eggs in one basket when it took its lead therapy into a Phase III trial on its own. And now that the anticoagulant study has been shelved after signs of a severe allergic reaction were seen among patients, the biotech is cutting more than half of its staffers in an effort to preserve cash and review what kind of moves it can still make.

Adaptimmune gathers $104M to fuel hot immuno-oncology tech race

A slate of top-tier biotech investors are coming in with a whopping $104 million Series A designed to take Oxford-based Adaptimmune--named a Fierce 15 company earlier in the week--well down the clinical path on its immuno-oncology tech.